...
首页> 外文期刊>Medicine. >Prognostic value of long non-coding RNA SNHG20 in cancer: A meta-analysis
【24h】

Prognostic value of long non-coding RNA SNHG20 in cancer: A meta-analysis

机译:长期非编码RNA SNHG20在癌症中的预后价值:META分析

获取原文

摘要

Background: Small nucleolar RNA host gene 20 ( SNHG20 ) is a newly identified long non-coding RNA (lncRNA). Accumulative evidence suggest that SNHG20 is highly related to tumorigenesis. However, whether the levels of SNHG20 can be used for prognosis of patients with different cancer types was unclear. The present study aims to explore the role of SNHG20 in tumor prognosis and its clinical significance. Methods: Related articles published before March 14, 2019 were searched in PubMed, Excerpta Medica Database (EMBASE), ISI Web of Science, and China National Knowledge Infrastructure (CNKI). Hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) were obtained using Stata 11.0 software and used to for determination of the link between the levels of SNHG20 and overall survival (OS). Fixed or random model was chosen depending on the heterogeneity of the studies. A quality assessment of the included studies was performed according to the Newcastle-Ottawa scale. This study was approved by the Medical Ethics Committee of Xiangya Hospital of Central South University. Results: After a strict filtering process, a total of 1149 patients from 15 studies were enrolled in this study. Pooled data showed that elevated level of SNHG20 was correlated not only with poor overall survival (HR = 2.49, 95% confidence interval (CI): 2.05–2.98), but also with tumor-node-metastasis stage (TNM) (odds ratio (OR) = 3.32, 95% CI: 2.27–4.86), high histological grade (OR = 2.11, 95% CI: 1.55–2.87), tumor size (OR = 2.92, 95% CI: 2.17–3.91), and lymph node metastasis (OR = 4.48, 95% CI: 2.90–6.92). Of note, there is no significant heterogeneity difference among the studies. Conclusion: Up-regulated SNHG20 predicts unfavorable prognosis for multiple kinds of cancers although further studies are in need to verify its clinical applications.
机译:背景:小核核瘤RNA宿主基因20(SNHG20)是一种新鉴定的长期非编码RNA(LNCRNA)。累积证据表明,SNHG20与肿瘤引发具有高度相关。然而,SNHG20的水平可用于不同癌症类型的预后不清楚。本研究旨在探讨SNHG20在肿瘤预后的作用及其临床意义。方法:在2019年3月14日之前发表的相关文章在PubMed,Excerpta Medica数据库(EMBASE),ISI Web和中国国家知识基础设施(CNKI)中搜查。使用STATA 11.0软件获得危险比(HRS)及其相应的95%置信区间(CIs),用于测定SNHG20水平和总存活(OS)之间的链接。根据研究的异质性选择固定或随机模型。根据纽卡斯尔 - 渥太华规模进行了对包括研究的质量评估。本研究由中南大学湘雅医院医疗伦理委员会批准。结果:经过严格的过滤过程,共有1149例研究患者参加了本研究。汇总数据显示,SNHG20的升高不仅具有差的整体存活率(HR = 2.49,95%置信区间(CI):2.05-2.98),还具有肿瘤节点转移阶段(TNM)(差距比(或)= 3.32,95%CI:2.27-4.86),高组织学等级(或= 2.11,95%CI:1.55-2.87),肿瘤大小(或= 2.92,95%CI:2.17-3.91)和淋巴结转移(或= 4.48,95%CI:2.90-6.92)。注意,研究中没有显着的异质性差异。结论:上调的SnHG20预测多种癌症的不利预后,尽管需要进一步研究验证其临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号